PTPRC and neoplasm: Co-immunostaining of CD4, CD8, CD3 and CD45 showed that TP-0903 treatment alone or in combination with WIN55212-2 significantly increased the amount of cytotoxic CD8+ T lymphocytes (CTLs) in tumor tissue, whereas it significantly decreased the percentages of CD4+ helper T lymphocytes (Th) infiltrating the tumor tissue (Figure 6C).